News

The bacterium Stenotrophomonas maltophilia in the lungs is significantly associated with a higher risk of death and hospitalization due to disease exacerbation in people with chronic obstructive pulmonary disease (COPD), a study shows. Researchers are calling for clinical trials to test whether targeting S. maltophilia with antibiotics might improve outcomes…

After hospitalization due to chronic obstructive pulmonary disease (COPD) exacerbation, patients who live in rural areas and/or have to drive long distances to get to lung specialty centers are more likely to be prescribed an inhaler therapy regimen that isn’t in line with medical guidelines. That’s according to a…

In the U.S., many people with diagnosed or probable chronic obstructive pulmonary disease (COPD) at higher risk of disease exacerbations are not receiving recommended care, a new study found. “This analysis reveals the gaps and opportunities for improvement in the identification and management of patients with COPD in the…

Increases in new onset or recurring depression were seen among older Canadian adults with chronic obstructive pulmonary disease (COPD) during the early stages of the COVID-19 pandemic, a study shows. One in six patients without a history of depression before the pandemic developed it early on in it. For…

The U.S. Food and Drug Administration (FDA) has agreed to review Verona Pharma’s application seeking approval of inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). FDA’s review team now has up to 10 months to examine all data filed with the new drug…

Lupin Pharmaceuticals has penned a deal with low-cost pharmacy Mark Cuban Cost Plus Drugs and the COPD Foundation to broaden access for patients in the U.S. to a generic option of an approved tiotropium bromide dry inhalation powder for chronic obstructive pulmonary disease (COPD). Used with the…

Tiotropium bromide dry inhalation powder for use with the LupinHaler device, a generic version of Spiriva HandiHaler, is now available in the U.S. as a maintenance treatment of chronic obstructive pulmonary disease (COPD), Lupin Pharmaceuticals announced. Generics are considered bioequivalent to their brand-name alternatives,…

The U.S. Food and Drug Administration (FDA) has issued a warning letter to AstraZeneca for making false or misleading claims about Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), its approved inhalation therapy for chronic obstructive pulmonary disease (COPD). According to the FDA, promotional material about Breztri distributed by AstraZeneca includes claims…

While smoking is a known risk factor for chronic obstructive pulmonary disease (COPD), heavy smokers can exhibit a series of respiratory symptoms without developing airflow blockage – one of the criteria to diagnose COPD – a study reports. The findings, which are based on the long-term follow-up of participants…

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…